Safety of intranasal corticosteroids
Article Sidebar
Published:
Dec 12, 2014
Keywords:
interanasal corticosteroids, safety, allergic rhinitis, nonallergic rhinitis, rhinosinusitis
Main Article Content
Abstract
Intranasal corticosteroids are currently the most effective anti-inflamatory drugs in the treatment of allergic rhinitis, acute and chronic rhinosunusitis and chronic rhinosinusitis with nasal polyps. Advantage of intranasal corticosteroids is their strong anti-inflammatory local action and little impact on general health. Newer agents with lower systemic availability may be preferable, and may come closer to the pharmacokinetic/ pharmacologic criteria for the ideal therapeutic choice.
Downloads
Download data is not yet available.
Article Details
How to Cite
Rapiejko , P., & Jurkiewicz , D. (2014). Safety of intranasal corticosteroids. Alergoprofil, 10(4), 16-21. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/820
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014, 22(10): 27-35.
2. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revison. J. Allergy Clin. Immunol. 2010, 126: 466-476.
3. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012, 50(1): 1-12.
4. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973, 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis. Otolaryngol. Pol. 2014, 68(2): 51-64.
7. Antczak-Marczak M., Kuna P.: Steroidofobii ciąg dalszy, czyli dobrze poznać wroga (a może przyjaciela?). Terapia 2008, 4: 55-63.
8. Kuna P.: Praktyczne zasady leczenia astmy. Terapia 2006, 4: 5-12.
9. Griner A.N., Hellings P.W., Rotiroti G. et al.: Allergic rhinitis. Lancet 2011, 378(9809): 2112-2122.
10. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009, 63(4): 324-330.
11. Samoliński B. (red.): ECAP – Epidemiologia Chorób Alergicznych w Polsce. Warszawski Uniwersytet Medyczny, Warszawa 2009.
12. [online:http://www.ecap.pl] (dostęp: 2014.12.01).
13. Emeryk A., Bartkowiak-Emeryk M., Emeryk-Maksymiuk J.: Glikokortykosteroidy wziewne w astmie – jakie, komu, jak? Alergoprofil 2011, 7(3): 2-9.
14. Kulus M., Martosiewicz W.: Miejsce monoterapii glikokortykosteroidami wziewnymi w świetle obecnych standardów terapii astmy. Alergoprofil 2011, 7(4): 2-4.
15. Rapiejko P.: Leczenie ostrego zapalenia zatok przynosowych. Alergoprofil 2008, 4(3): 11-17.
16. Hellings P.W., Fokkens W.J., Akdis C. et al.: Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013, 68(1): 1-7.
17. Arcimowicz M.: Glikokortykosteroidy donosowe u dzieci. Alergoprofil 2012, 8(1): 5-17.
18. Rapiejko P.: Donosowe glikokortykosteroidy w leczeniu chorób nosa i zatok przynosowych. Terapia 2012, 12(282): 61-66.
19. Rapiejko P., Jurkiewicz D.: Zapalenie zatok przynosowych. Terapia 2011, 11-12(265): 31-40.
20. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000, 55: 16-33.
21. Baumann D., Bachert C., Hogger P.: Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clinical & Experimental Allergy 2009, 39(10): 1540-1550.
22. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008, 63: 1292-1300.
23. Daley-Yates P.T., Kunka R.I., Yin I. et al.: Bioavailability of fluticasone propionate and mometasone furate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004, 60: 265-268.
24. Allen D.B.: Systemic effects of intranasal steroids: An endocrinologist’s perspective. J. Allergy Clin. Immunol. 2000, 106: S179-S190.
25. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of Growth Retardation in Children with Perennial Allergic Rhinitis after One Year of Treatment with Mometasone Furoate Aqueous Nasal Spray. Pediatrics 2000, 105: e22.
26. Sastre J., Mosges R.: Local and Systemic Safety of Intranasal Corticosteroids. J. Investig. Allergol. Clin. Immunol. 2012,22(1): 1-12.
27. Minshal E.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998, 118: 648-654.
2. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revison. J. Allergy Clin. Immunol. 2010, 126: 466-476.
3. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012, 50(1): 1-12.
4. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973, 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis. Otolaryngol. Pol. 2014, 68(2): 51-64.
7. Antczak-Marczak M., Kuna P.: Steroidofobii ciąg dalszy, czyli dobrze poznać wroga (a może przyjaciela?). Terapia 2008, 4: 55-63.
8. Kuna P.: Praktyczne zasady leczenia astmy. Terapia 2006, 4: 5-12.
9. Griner A.N., Hellings P.W., Rotiroti G. et al.: Allergic rhinitis. Lancet 2011, 378(9809): 2112-2122.
10. Samoliński B., Sybilski A.J., Raciborski F. et al.: Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009, 63(4): 324-330.
11. Samoliński B. (red.): ECAP – Epidemiologia Chorób Alergicznych w Polsce. Warszawski Uniwersytet Medyczny, Warszawa 2009.
12. [online:http://www.ecap.pl] (dostęp: 2014.12.01).
13. Emeryk A., Bartkowiak-Emeryk M., Emeryk-Maksymiuk J.: Glikokortykosteroidy wziewne w astmie – jakie, komu, jak? Alergoprofil 2011, 7(3): 2-9.
14. Kulus M., Martosiewicz W.: Miejsce monoterapii glikokortykosteroidami wziewnymi w świetle obecnych standardów terapii astmy. Alergoprofil 2011, 7(4): 2-4.
15. Rapiejko P.: Leczenie ostrego zapalenia zatok przynosowych. Alergoprofil 2008, 4(3): 11-17.
16. Hellings P.W., Fokkens W.J., Akdis C. et al.: Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013, 68(1): 1-7.
17. Arcimowicz M.: Glikokortykosteroidy donosowe u dzieci. Alergoprofil 2012, 8(1): 5-17.
18. Rapiejko P.: Donosowe glikokortykosteroidy w leczeniu chorób nosa i zatok przynosowych. Terapia 2012, 12(282): 61-66.
19. Rapiejko P., Jurkiewicz D.: Zapalenie zatok przynosowych. Terapia 2011, 11-12(265): 31-40.
20. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000, 55: 16-33.
21. Baumann D., Bachert C., Hogger P.: Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clinical & Experimental Allergy 2009, 39(10): 1540-1550.
22. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 2008, 63: 1292-1300.
23. Daley-Yates P.T., Kunka R.I., Yin I. et al.: Bioavailability of fluticasone propionate and mometasone furate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004, 60: 265-268.
24. Allen D.B.: Systemic effects of intranasal steroids: An endocrinologist’s perspective. J. Allergy Clin. Immunol. 2000, 106: S179-S190.
25. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of Growth Retardation in Children with Perennial Allergic Rhinitis after One Year of Treatment with Mometasone Furoate Aqueous Nasal Spray. Pediatrics 2000, 105: e22.
26. Sastre J., Mosges R.: Local and Systemic Safety of Intranasal Corticosteroids. J. Investig. Allergol. Clin. Immunol. 2012,22(1): 1-12.
27. Minshal E.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998, 118: 648-654.